Imaavy™

Understanding Imaavy®
Imaavy® (nipocalimab‑aahu) is a monoclonal antibody that helps regulate the immune system by blocking the neonatal Fc receptor (FcRn). This prevents the recycling of harmful IgG antibodies that attack the connection between nerves and muscles in people with generalized myasthenia gravis (gMG). It is used to treat adults and children 12 years and older who test positive for anti‑AChR or anti‑MuSK antibodies.

How Imaavy™ Works:

• Targets and blocks FcRn to lower harmful IgG autoantibody levels.
• Helps improve muscle strength and reduce weakness and fatigue in gMG.
• Supports daily activities such as talking, chewing, swallowing, and walking.
• Provides lasting disease control with treatment every two weeks.

FDA Approval:
2025 – Approved for the treatment of generalized myasthenia gravis in patients 12 years and older who are anti‑AChR or anti‑MuSK antibody positive.

For more information, please visit the Imaavy patient website. Speak with your healthcare provider to determine if Imaavy is the right treatment option for you.